USPTO Examiner CHANDRAKUMAR NIZAL S - Art Unit 1625

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19327867MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOFSeptember 2025March 2026Allow611YesNo
19258335ROUTE FOR CONSTRUCTING CHIRAL FRAGMENT OF FEZOLINETANT, INTERMEDIATE THEREOF, AND PREPARATION METHOD THEREFORJuly 2025December 2025Allow601YesNo
19048594DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USEFebruary 2025July 2025Allow621YesNo
19040329TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTHJanuary 2025May 2025Allow301YesNo
18904330KRAS Proteolysis Targeting ChimerasOctober 2024December 2025Allow1531NoNo
18820232USE OF REBOXETINE TO TREAT NARCOLEPSYAugust 2024March 2025Allow630YesNo
18809602CATALYSTS FOR SYNTHESIZING CYCLIC CARBONATES, PREPARATION METHODS AND USES THEREOFAugust 2024August 2025Allow1221NoNo
18809731DEVICE AND METHOD FOR PRODUCING HIGH-PRESSURE OR SUPER HIGH-PRESSURE STEAM AS BYPRODUCT FROM MALEIC ANHYDRIDE PRODUCING DEVICEAugust 2024April 2025Allow811YesNo
18787536Systems and methods for the production of levulinic acid, furfural, and formic acidJuly 2024October 2024Allow200YesNo
18765167SYNTHETIC PROGESTOGENS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAMEJuly 2024December 2024Allow510NoNo
18670653LOW-TEMPERATURE CONTINUOUS-FLOW PREPARATION METHOD OF BEDAQUILINEMay 2024July 2024Allow200NoNo
18657519READY-TO-ADMINISTER HYDROMORPHONE FORMULATIONSMay 2024September 2025Allow1601YesNo
18654002BIMETALLIC METAL-ORGANIC FRAMEWORKS NANOSHEET BASED ON ZEOLITE IMIDAZOLE FRAMEWORK/MATERIALS OF INSTITUTE LAVOISIER TOPOLOGY AND PREPARATION METHOD AND APPLICATION THEREOFMay 2024October 2024Allow501NoNo
184432283-SUBSTITUTED PIPERIDINE COMPOUNDS FOR CBL-B INHIBITION, AND USE THEREOFFebruary 2024July 2025Allow1711YesNo
18419104METHODS OF TREATING NEUROLOGICAL AND OTHER DISORDERS USING ENANTIOPURE DEUTERIUM-ENRICHED BUPROPIONJanuary 2024August 2025Abandon1810NoNo
18573904NOVEL BIFUNCTIONAL HETEROCYCLIC COMPOUND HAVING BTK DEGRADATION FUNCTION VIA UBIQUITIN PROTEASOME PATHWAY, AND USE THEREOFDecember 2023June 2024Allow600YesNo
18541304SUBSTITUTED ETHYLAMINE FUSED HETEROCYCLIC MESCALINE DERIVATIVESDecember 2023August 2025Allow2041NoNo
18538443DRUG FOR TREATING OR PREVENTING CEREBRAL HEMORRHAGE, AND METHOD FOR TREATING OR PREVENTING CEREBRAL HEMORRHAGE USING THE DRUGDecember 2023July 2025Allow1910YesNo
18532307PROCESSES AND INTERMEDIATES FOR THE PREPARATIONS OF BENZOPROSTACYCLIN ANALOGUES AND BENZOPROSTACYCLIN ANALOGUES PREPARED THEREFROMDecember 2023October 2025Allow2220NoNo
18529306FORMULATIONSDecember 2023October 2025Allow2221YesNo
185295156-(4-HYDROXYPHENYL)-2-(2-ETHOXYETHOXY)-4-(4-METHOXYPHENYL)NICOTINONITRILE AS AN ANTIMICROBIAL COMPOUNDDecember 2023July 2024Allow721YesNo
18521663SUBSTITUTED 3-((3-AMINOPHENYL)AMINO)PIPERIDINE-2,6-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITHNovember 2023April 2025Allow1701NoNo
18516230Bromodomain InhibitorsNovember 2023October 2025Abandon2310NoNo
185081641,4-DIVINYLPHENYLENE-BRIDGED DIRUTHENIUM COMPLEX BEARING TWO Ru(CO)(PiPR3)2 MOIETIES WITH 8-MERCAPTOQUINOLATO CO-LIGAND AS AN ORGANIC CATALYSTNovember 2023December 2024Allow1321NoNo
18386447COMPOSITION, FORMULATIONS AND METHODS OF MAKING AND USING BOTANICALS AND NATURAL COMPOUNDS FOR THE PROMOTION OF HEALTHY BRAIN AGINGNovember 2023March 2026Abandon2811NoNo
183855788-((3,4-DIHYDROXYPHENYL)DIAZENYL)NAPHTHALENE-1,3-DISULFONIC ACID AS AN ANTIOXIDANT COMPOUNDOctober 2023February 2025Allow1530NoYes
183855618-((4-HYDROXY-3-METHYLPHENYL)DIAZENYL)NAPHTHALENE-1,3-DISULFONIC ACID AS AN ANTIMICROBIAL COMPOUNDOctober 2023June 2025Abandon1940NoNo
183847718-((3-FORMYL-4-HYDROXYPHENYL)DIAZENYL)NAPHTHALENE-1,3-DISULFONIC ACID AS AN ANTIOXIDANT COMPOUNDOctober 2023February 2025Allow1630YesYes
183847858-[(2-HYDROXYNAPHTHALEN-1-YL)DIAZENYL]NAPHTHALENE-1,3-DISULFONIC ACID AS AN ANTIOXIDANT COMPOUNDOctober 2023May 2025Abandon1830NoNo
18384197FUSED BICYCLIC ALKYLENE LINKED IMIDODICARBONIMIDIC DIAMIDES, METHODS FOR SYNTHESIS, AND USES IN THERAPYOctober 2023March 2025Allow1711YesNo
18383949TETRAZOLE CONTAINING APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOFOctober 2023July 2025Allow2011YesNo
18492874COMPOUNDS AND COMPOSITIONS FOR NEMATODE TREATMENTOctober 2023November 2025Allow2420YesNo
18492746PROTEOLYSIS-TARGETING CHIMERIC MOLECULES (PROTACS) THAT INDUCE DEGRADATION OF INDOLEAMINE 2,3-DIOXYGENASE (IDO) PROTEINOctober 2023January 2025Allow1500YesNo
18379559N-(NAPHTHALEN-1-YLCARBAMOTHIOYL)FURAN-2-CARBOXAMIDE AS AN ECO-FRIENDLY INSECTICIDAL AGENT AGAINST SPODOPTERA LITTORALIS (BOISD.)October 2023December 2023Allow200YesNo
18484858NOVEL MODULATORS OF THE SIGMA-2 RECEPTOR AND THEIR METHOD OF USEOctober 2023November 2025Allow2511NoNo
18475724TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTHSeptember 2023February 2025Allow1611NoNo
18467441PROCESSES AND INTERMEDIATES FOR THE PREPARATIONS OF BENZOPROSTACYCLIN ANALOGUES AND BENZOPROSTACYCLIN ANALOGUES PREPARED THEREFROMSeptember 2023September 2025Allow2411NoNo
18464352SOLUTIONS FOR ENHANCING THE EFFECTIVENESS OF INSECTICIDES AND FUNGICIDES ON LIVING PLANTS AND RELATED METHODSSeptember 2023September 2025Allow2411YesNo
18445510Deuterated FluorophoresSeptember 2023October 2025Allow2611YesNo
18242203CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USESeptember 2023October 2025Abandon2511NoNo
18233090CONTRACEPTIVE COMPOUNDS AND METHODSAugust 2023December 2024Allow1600YesNo
18365877SYNTHETIC PROGESTOGENS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAMEAugust 2023February 2024Allow610YesNo
18229353PLK1 SELECTIVE DEGRADATION INDUCING COMPOUNDAugust 2023July 2025Abandon2301NoNo
18363994CRYSTALLINE SOLID FORMS OF N-{4-[(6,7-DIMETHOXYQUINOLIN-4-YL)OXY]PHENYL}-N'-(4-FLUOROPHENYL) CYCLOPROPANE-1,1-DICARBOXAMIDE, PROCESSES FOR MAKING, AND METHODS OF USEAugust 2023July 2025Allow2411YesNo
18352791A PEPTIDE SAPORIN CONJUGATE FOR THE TREATMENT OF CANCERJuly 2023November 2025Allow2821YesNo
18220856CANNABIS BASED THERAPEUTIC AND METHOD OF USEJuly 2023July 2025Allow2410NoNo
18347808ULTRA SHORT ACTING ANTI-ARRHYTHMIC AGENTSJuly 2023November 2024Allow1600YesNo
18339227MACROCYCLIC COMPOUND AND USES THEREOFJune 2023May 2025Allow2311NoNo
18209699BROMOCRIPTINE FORMULATIONSJune 2023December 2024Allow1800YesNo
18206953PROCESS OF MAKING DERIVATIVES OF SUBSTITUTED MORPHOLINESJune 2023December 2023Allow610YesNo
18204566ALPHA POLYGLUTAMATED PEMETREXED AND USES THEREOFJune 2023June 2025Allow2410YesNo
18254089AMIDE COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOFMay 2023February 2026Allow3210YesNo
18318939AROMATIC BORON-CONTAINING COMPOUNDS AND RELATED INSULIN ANALOGSMay 2023December 2023Allow6001YesNo
18318158METHODS, COMPOSITIONS, AND KITS ADDRESSING DEPRESSED MOODMay 2023June 2025Abandon2501NoNo
18141999DEUTERATED ANALOGS OF ETIFOXINE, THEIR DERIVATIVES AND USES THEREOFMay 2023June 2025Allow2510YesNo
18307174SUBSTITUTED ALKYLPHENOLS AS HCN1 ANTAGONISTSApril 2023November 2024Allow1900YesNo
18305611FREE BASE CRYSTALLINE FORM OF A COMPLEMENT COMPONENT C5a RECEPTORApril 2023June 2025Abandon2610NoNo
18304764ORGANIC ELECTRO-OPTIC CHROMOPHORESApril 2023March 2025Allow2301YesNo
18137766CANNABINOID CONJUGATE MOLECULESApril 2023November 2023Allow701YesNo
18304411Synthesis and Composition of Neurolenin D Mesylate and Related Compounds - New Drugs for the Treatment of Parasitic Nematode Infections in Humans, Animals and PlantsApril 2023February 2026Allow3401YesNo
18303267USE OF TRANS-[TETRACHLOROBIS(1H-INDAZOLE)RUTHENATE(III)] FOR THE TREATMENT OF CANCERApril 2023June 2025Abandon2610YesNo
18135225COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURYApril 2023June 2025Abandon2610YesNo
18297973ORAL CANNABINOID PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING SLEEP DISORDERSApril 2023July 2023Allow300NoNo
18131052CANNABIS BASED THERAPEUTIC AND METHOD OF USEApril 2023March 2025Allow2410YesNo
18130178CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) INHIBITOR AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAID INHIBITOR FOR USE IN THE TREATMENT OR PREVENTION OF CARDIOVASCULAR DISEASESApril 2023September 2024Allow1701YesNo
18029289PYRIMIDINE-AND NITROGEN-CONTAINING BICYCLIC COMPOUNDMarch 2023December 2025Allow3301NoNo
18185555SOLID FORMS COMPRISING AN OXIME ETHER COMPOUND, COMPOSITIONS AND METHODS OF USE THEREOFMarch 2023May 2025Abandon2601NoNo
18121694HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORSMarch 2023October 2024Allow1910YesNo
18119564PROLONGED ECTOPARASITE-CONTROLLING AGENT FOR ANIMALMarch 2023March 2025Allow2520YesNo
18119751COUMARIN COMPOUNDS AS ANTIBACTERIAL AGENTSMarch 2023December 2023Allow920YesNo
18117328CREATINE AND/OR CREATININE COMPOSITIONS AND RELATED METHODSMarch 2023February 2026Allow3610YesNo
18117257Compositions and Methods of Modulating Short-Chain Dehydrogenase ActivityMarch 2023June 2025Abandon2711YesNo
18115966TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTHMarch 2023May 2024Allow1400YesNo
18114055BORATE SALTS, POLYMERS AND COMPOSITESFebruary 2023July 2024Allow1601NoNo
18169716BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSESFebruary 2023September 2024Allow1910NoNo
18168583CRYSTALLINE FORMS OF BENZAMIDE COMPOUND AND PROCESS FOR PREPARING THE SAMEFebruary 2023March 2026Abandon3701YesNo
18157593CO-CRYSTALS OF BOSCALID AND TRIAZOLESJanuary 2023July 2024Allow1801YesNo
18096272COMPOUNDS WITH HIV MATURATION INHIBITORY ACTIVITYJanuary 2023April 2025Abandon2711NoNo
18152098DENDRILLA MEMBRANOSA COMPOUNDS, DERIVATIVES THEREOF, AND USES THEREOFJanuary 2023February 2025Allow2521NoNo
18013375INTERMEDIATE FOR SYNTHESIZING CAMPTOTHECIN DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOFDecember 2022November 2025Allow3401YesNo
18003226CYCLOBUTYL-UREA DERIVATIVESDecember 2022March 2026Abandon3901NoNo
18002932PHARMACEUTICAL COMPOSITIONS COMPRISING NITROXOLINE LYSINATE, PREPARATION METHOD THEREFOR AND USE THEREOFDecember 2022March 2026Allow3811NoNo
18069943METHOD FOR MANUFACTURING METHYLTETRAHYDROPHTHALIC ANHYDRIDEDecember 2022August 2024Allow6030YesNo
18068700IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOFDecember 2022January 2026Allow3721YesNo
18011646USE OF COMPOSITION IN TREATMENT OF CEREBRAL STROKEDecember 2022January 2026Allow3720YesNo
18084307AMINO ACID COMPOUNDS AND METHODS OF USEDecember 2022May 2024Allow1700YesNo
18067456READY-TO-USE BARRIER AND KNOCKDOWN PESTICIDESDecember 2022January 2024Allow1321YesNo
18082973Methods of Treating Residual Lesions of Vascular AnomaliesDecember 2022May 2025Abandon2920YesNo
18062683Fospropofol Salts, Methods And CompositionsDecember 2022March 2025Allow2720YesNo
18075664CHEMICAL COMPOUNDSDecember 2022December 2024Abandon2401NoNo
17990427CD16A BINDING AGENTS AND USES THEREOFNovember 2022July 2024Allow1901YesNo
17925923ANTI-CANCER SPIROCYCLIC-GUANIDINE COMPOUNDS AND USES THEREOFNovember 2022June 2025Allow3100YesNo
18055282System and Method for Making Cannabinoid Nanoparticle Carrier CompositionNovember 2022August 2025Allow3300YesNo
17983563CHIRAL MULTIDENTATE LIGAND, AND APPLICATION THEREOF IN ASYMMETRIC HYDROGENATIONNovember 2022October 2025Allow3501YesNo
17982859CANNABINOID CONJUGATE MOLECULESNovember 2022March 2023Allow401YesNo
17982779CANNABINOID CONJUGATE MOLECULESNovember 2022March 2023Allow501YesNo
17982233THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDSNovember 2022February 2025Allow2711YesNo
17922790COMPOSITIONS OF TRYPTOPHOL DERIVATIVES AND 4-ETHYL-PHENOL DERIVATIVES, AND METHODS OF USING SAMENovember 2022July 2025Allow3300YesNo
17977349E PROTEIN CHANNEL BLOCKERS AND ORF3 INHIBITORS AS ANTI-COVID-19 AGENTSOctober 2022February 2026Abandon3901NoNo
17974804COMPOSITIONS COMPRISING IBRUTINIB AND AN ALKALOID HAVING ENHANCED BIOAVAILABILITYOctober 2022May 2025Abandon3021NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner CHANDRAKUMAR, NIZAL S.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
5
Examiner Affirmed
4
(80.0%)
Examiner Reversed
1
(20.0%)
Reversal Percentile
31.0%
Lower than average

What This Means

With a 20.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
98
Allowed After Appeal Filing
37
(37.8%)
Not Allowed After Appeal Filing
61
(62.2%)
Filing Benefit Percentile
62.4%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 37.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Examiner CHANDRAKUMAR, NIZAL S - Prosecution Strategy Guide

Executive Summary

Examiner CHANDRAKUMAR, NIZAL S works in Art Unit 1625 and has examined 2,456 patent applications in our dataset. With an allowance rate of 73.1%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 23 months.

Allowance Patterns

Examiner CHANDRAKUMAR, NIZAL S's allowance rate of 73.1% places them in the 37% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.

Office Action Patterns

On average, applications examined by CHANDRAKUMAR, NIZAL S receive 1.27 office actions before reaching final disposition. This places the examiner in the 17% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by CHANDRAKUMAR, NIZAL S is 23 months. This places the examiner in the 85% percentile for prosecution speed. Applications move through prosecution relatively quickly with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +23.6% benefit to allowance rate for applications examined by CHANDRAKUMAR, NIZAL S. This interview benefit is in the 70% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 35.9% of applications are subsequently allowed. This success rate is in the 81% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 62.3% of cases where such amendments are filed. This entry rate is in the 87% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 154.5% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 90% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 93.3% of appeals filed. This is in the 85% percentile among all examiners. Of these withdrawals, 77.1% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 61.3% are granted (fully or in part). This grant rate is in the 66% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 10.7% of allowed cases (in the 94% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 7.2% of allowed cases (in the 85% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Consider after-final amendments: This examiner frequently enters after-final amendments. If you can clearly overcome rejections with claim amendments, file an after-final amendment before resorting to an RCE.
  • RCEs are effective: This examiner has a high allowance rate after RCE compared to others. If you receive a final rejection and have substantive amendments or arguments, an RCE is likely to be successful.
  • Request pre-appeal conferences: PACs are highly effective with this examiner. Before filing a full appeal brief, request a PAC to potentially resolve issues without full PTAB review.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.